Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy

Karim, Mohammed Yousuf; Pisoni, C. N.; Ferro, Laura; Tungekar, M. F.; Abbs, I C; D’Cruz, David; Khamashta, Munther A.; Hughes, G. R. V.

doi:10.1093/rheumatology/kei019

Cited by 43 publications

(24 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nowadays mycophenolate mofetile has been considered an important alternate agent for refractory lupus nephritis with hopeful results and reasonable side effects (Chan et al 2000, 2005; Lenz et al 2005; Weng et al 2010; Zhu et al 2007; Ong et al 2005; Karim et al 2005). Mycophenolic acid, the active metabolite of mycophenolate mofetil , selectively suppresses the proliferation of T and B lymphocyte, the formation of antibodies, and the glycosylation of adhesion molecules by inhibiting purine nucleotide synthesis and depleting lymphocytes and monocytes of guanosine triphosphate (Eickenberg et al 2012).…”

Section: Introductionmentioning

confidence: 99%

Efficacy of long-term maintenance therapy with mycophenolate mofetil in lupus nephritis

Rezaieyazdi

Tavakoli²,

Khajehdaluee

et al. 2014

SpringerPlus

View full text Add to dashboard Cite

BackgroundMycophenolate mofetil (MMF) has long been used to manage lupus nephritis. Despite research on its long-term efficacy, it is still warranted to conduct further investigation regarding its indications, safety and outcome. This study was intended to evaluate our proposed protocol in maintenance therapy with MMF.Twenty-four lupus nephritis patients were registered prior to their receiving 3–6 month induction therapy with monthly iv pulses of cyclophosphamide (CYC), followed by 24 month maintenance therapy using MMF and steroid. We defined end points as achievement of complete and partial remission, relapse, refractory to therapy as well as end stage renal disease (ESRD) and death. Friedman and repeated measurement tests were used to assess the effect of treatment on parameters over time.Complete renal remission was achieved in 79.16% until the end of the last follow up with an average period of 12.45 ± 7.37 months since treatment commenced. Significant statistical differences were seen regarding proteinuria, hematuria, leukocyturia, plasma creatinine, C3, C4 before and after therapy (P < 0.05): plasma creatinine and proteinurea falling from 0.96 ± 0.65 to 0.75 ± 0.19 mg/dl (P < 0.14) and from 1.64 ± 1.12 to 0.27 ± 0.60 gr/24 h (P < 0.001). By the end of 24-month, 95.8% of patients had been in remission. Four episodes of relapse ended in remission followed by retreatment. No life-threatening side effects were observed in 66.6% of patients with fourteen cases of infection (58.3%). None of them developed ESRD.Maintenance therapy with MMF was shown to yield favorable outcome with minimal complications, in treating lupus nephritis (IRCT2012071710313N1).

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of long-term maintenance therapy with mycophenolate mofetil in lupus nephritis

Rezaieyazdi

Tavakoli²,

Khajehdaluee

et al. 2014

SpringerPlus

View full text Add to dashboard Cite

show abstract

“…In a study that included ten class V lupus nephritis patients who were treated with MMF and followed for a mean of 15.4 months (range 3-52 months), daily proteinuria was reduced from a median of 2.26 g to a median of 0.66 g [12]. Therefore, serum albumin levels increased after treatment.…”

Section: Discussionmentioning

confidence: 99%

The effect of mycophenolate mofetil on primary and secondary treatment of primary glomerulonephritis and lupus nephritis

et al. 2008

View full text Add to dashboard Cite

show abstract

“…The benefits of MMF for lupus nephritis were first provided by uncontrolled studies [30][31][32][33] of patients refractory to cyclophosphamide. Subsequently, randomized controlled trials have been performed [34-38,39 ,40].…”

Section: Mycophenolate Mofetil: Remission Induction Therapymentioning

confidence: 99%

What is the value of mycophenolate mofetil as induction and maintenance therapy in lupus nephritis?

Jones

Walsh²,

Smith³

2009

Current Opinion in Rheumatology

View full text Add to dashboard Cite

MMF is likely to be noninferior to cyclophosphamide for the induction of remission in lupus nephritis. Early results suggest that MMF is equivalent to azathioprine for remission maintenance, although large randomized trial data are awaited to clarify the role. The optimal dosing strategy and duration of MMF treatment have not been established. The efficacy and safety of MMF in patients with severe renal impairment requires further investigation. Longer follow-up is required to fully assess the impact of MMF on renal survival and overall mortality.

show abstract

Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy

Abstract: MMF is a potentially useful immunosuppressive agent in reducing the proteinuria associated with membranous predominant LN.

Cited by 43 publications

References 16 publications

Efficacy of long-term maintenance therapy with mycophenolate mofetil in lupus nephritis

Efficacy of long-term maintenance therapy with mycophenolate mofetil in lupus nephritis

The effect of mycophenolate mofetil on primary and secondary treatment of primary glomerulonephritis and lupus nephritis

What is the value of mycophenolate mofetil as induction and maintenance therapy in lupus nephritis?

Contact Info

Product

Resources

About